Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial

Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial. Lebellec, L.; Bertucci, F.; Tresch-Bruneel, E.; Ray-Coquard, I.; Le Cesne, A.; Bompas, E.; Blay, J. Y.; Italiano, A.; Mir, O.; Ryckewaert, T.; Toiron, Y.; Camoin, L.; Goncalves, A.; Penel, N.; Le Deley, M. C.. BMC Cancer. 2018; 963: p.963. doi:10.1186/s12885-018-4828-1
Article